Conversion of liver allograft recipients from cyclosporine to FK506 immunosuppressive therapy— a clinicopathologic study of 96 patients

A. J. Demetris, J. J. Fung, S. Todo, J. McCauley, A. Jain, S. Takaya, M. Alessiani, K. Abu-Elmagd, D. H. Van Thiel, T. E. Starzl

Research output: Contribution to journalArticle

105 Citations (Scopus)

Abstract

The effect of conversion from cyclosporine-steroid immunosuppression to the new agent FK506 was studied in 96 liver allograft recipients who were experiencing graft dysfunction or cyclosporine toxicity. Patients were stratified according to the cause of graft dysfunction that ultimately led to conversion to FK506. Response to FK506 introduction was monitored pathologically and biochemically. The outcome of a switch from CsA to FK506 was highly favorable in patients experiencing acute and the early stages of chronic rejection, despite optimal conventional therapy. Patients with later stages of chronic rejection did not respond to conversion to FK506 and most eventually lost their liver grafts in this process. Patients in whom we had difficulty separating chronic rejection from chronic persistent or low-grade chronic active hepatitis were mostly unaffected by conversion to FK506. Active hepatitis was a poor indication for conversion, because most of the patients experienced graft failure or died from liver failure. As a group, there was no statistically significant change in renal function 180 days after conversion to FK506. These findings expand the experience with FK506 in human liver allograft recipients.

Original languageEnglish (US)
Pages (from-to)1056-1062
Number of pages7
JournalTransplantation
Volume53
Issue number5
DOIs
StatePublished - May 1992

Fingerprint

Tacrolimus
Immunosuppressive Agents
Cyclosporine
Allografts
Liver
Transplants
Therapeutics
Liver Failure
Chronic Hepatitis
Immunosuppression
Hepatitis
Steroids
Kidney

All Science Journal Classification (ASJC) codes

  • Transplantation

Cite this

Demetris, A. J. ; Fung, J. J. ; Todo, S. ; McCauley, J. ; Jain, A. ; Takaya, S. ; Alessiani, M. ; Abu-Elmagd, K. ; Van Thiel, D. H. ; Starzl, T. E. / Conversion of liver allograft recipients from cyclosporine to FK506 immunosuppressive therapy— a clinicopathologic study of 96 patients. In: Transplantation. 1992 ; Vol. 53, No. 5. pp. 1056-1062.
@article{df597810b70e46a3a15e852a59877edb,
title = "Conversion of liver allograft recipients from cyclosporine to FK506 immunosuppressive therapy— a clinicopathologic study of 96 patients",
abstract = "The effect of conversion from cyclosporine-steroid immunosuppression to the new agent FK506 was studied in 96 liver allograft recipients who were experiencing graft dysfunction or cyclosporine toxicity. Patients were stratified according to the cause of graft dysfunction that ultimately led to conversion to FK506. Response to FK506 introduction was monitored pathologically and biochemically. The outcome of a switch from CsA to FK506 was highly favorable in patients experiencing acute and the early stages of chronic rejection, despite optimal conventional therapy. Patients with later stages of chronic rejection did not respond to conversion to FK506 and most eventually lost their liver grafts in this process. Patients in whom we had difficulty separating chronic rejection from chronic persistent or low-grade chronic active hepatitis were mostly unaffected by conversion to FK506. Active hepatitis was a poor indication for conversion, because most of the patients experienced graft failure or died from liver failure. As a group, there was no statistically significant change in renal function 180 days after conversion to FK506. These findings expand the experience with FK506 in human liver allograft recipients.",
author = "Demetris, {A. J.} and Fung, {J. J.} and S. Todo and J. McCauley and A. Jain and S. Takaya and M. Alessiani and K. Abu-Elmagd and {Van Thiel}, {D. H.} and Starzl, {T. E.}",
year = "1992",
month = "5",
doi = "10.1097/00007890-199205000-00017",
language = "English (US)",
volume = "53",
pages = "1056--1062",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

Demetris, AJ, Fung, JJ, Todo, S, McCauley, J, Jain, A, Takaya, S, Alessiani, M, Abu-Elmagd, K, Van Thiel, DH & Starzl, TE 1992, 'Conversion of liver allograft recipients from cyclosporine to FK506 immunosuppressive therapy— a clinicopathologic study of 96 patients', Transplantation, vol. 53, no. 5, pp. 1056-1062. https://doi.org/10.1097/00007890-199205000-00017

Conversion of liver allograft recipients from cyclosporine to FK506 immunosuppressive therapy— a clinicopathologic study of 96 patients. / Demetris, A. J.; Fung, J. J.; Todo, S.; McCauley, J.; Jain, A.; Takaya, S.; Alessiani, M.; Abu-Elmagd, K.; Van Thiel, D. H.; Starzl, T. E.

In: Transplantation, Vol. 53, No. 5, 05.1992, p. 1056-1062.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Conversion of liver allograft recipients from cyclosporine to FK506 immunosuppressive therapy— a clinicopathologic study of 96 patients

AU - Demetris, A. J.

AU - Fung, J. J.

AU - Todo, S.

AU - McCauley, J.

AU - Jain, A.

AU - Takaya, S.

AU - Alessiani, M.

AU - Abu-Elmagd, K.

AU - Van Thiel, D. H.

AU - Starzl, T. E.

PY - 1992/5

Y1 - 1992/5

N2 - The effect of conversion from cyclosporine-steroid immunosuppression to the new agent FK506 was studied in 96 liver allograft recipients who were experiencing graft dysfunction or cyclosporine toxicity. Patients were stratified according to the cause of graft dysfunction that ultimately led to conversion to FK506. Response to FK506 introduction was monitored pathologically and biochemically. The outcome of a switch from CsA to FK506 was highly favorable in patients experiencing acute and the early stages of chronic rejection, despite optimal conventional therapy. Patients with later stages of chronic rejection did not respond to conversion to FK506 and most eventually lost their liver grafts in this process. Patients in whom we had difficulty separating chronic rejection from chronic persistent or low-grade chronic active hepatitis were mostly unaffected by conversion to FK506. Active hepatitis was a poor indication for conversion, because most of the patients experienced graft failure or died from liver failure. As a group, there was no statistically significant change in renal function 180 days after conversion to FK506. These findings expand the experience with FK506 in human liver allograft recipients.

AB - The effect of conversion from cyclosporine-steroid immunosuppression to the new agent FK506 was studied in 96 liver allograft recipients who were experiencing graft dysfunction or cyclosporine toxicity. Patients were stratified according to the cause of graft dysfunction that ultimately led to conversion to FK506. Response to FK506 introduction was monitored pathologically and biochemically. The outcome of a switch from CsA to FK506 was highly favorable in patients experiencing acute and the early stages of chronic rejection, despite optimal conventional therapy. Patients with later stages of chronic rejection did not respond to conversion to FK506 and most eventually lost their liver grafts in this process. Patients in whom we had difficulty separating chronic rejection from chronic persistent or low-grade chronic active hepatitis were mostly unaffected by conversion to FK506. Active hepatitis was a poor indication for conversion, because most of the patients experienced graft failure or died from liver failure. As a group, there was no statistically significant change in renal function 180 days after conversion to FK506. These findings expand the experience with FK506 in human liver allograft recipients.

UR - http://www.scopus.com/inward/record.url?scp=0026623559&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026623559&partnerID=8YFLogxK

U2 - 10.1097/00007890-199205000-00017

DO - 10.1097/00007890-199205000-00017

M3 - Article

C2 - 1374944

AN - SCOPUS:0026623559

VL - 53

SP - 1056

EP - 1062

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 5

ER -